OcuSciences Inc announced the US Food and Drug Administration (FDA) has granted marketing clearance for its OcuMet Beacon, the company’s proprietary, noninvasive tool for assessing retinal health. The confocal scanning ophthalmoscope device is indicated for infrared and autofluorescence imaging of the retina with or without the use of a mydriatic agent.

According to a company news release, the OcuMet Beacon retinal imager captures a naturally occurring fluorescence from the eye using proprietary illumination and detection technology, while advanced software helps visualize the functional image signature. It requires no injections, dyes, or physical contact with the eye. Because capturing the unique fluorescent signature only requires a few minutes per patient, the assessment is easy to integrate into routine eye exams and to pair with standard of care treatments, OcuSciences said.

“The OcuMet Beacon provides clinicians with valuable information in just seconds,” said Kurt Riegger, CEO of OcuSciences, in the news release. “This is a game-changer for the many patients and ophthalmologists who stand to benefit from more precise and deeper insight.”